Loading quotes...

Forecast

The analysts' average price target is €30.48 (+76.70%). The median is €30.48 (+76.70%).

Buy
  10
Hold
  3
Sell
  0

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Vor Biopharma advances telitacicept pipeline after Citigroup biopharma summit

    Vor Biopharma presented an accelerated development and commercialization strategy for telitacicept at the Citigroup biopharma summit. Recruitment for the Phase III study in myasthenia gravis was completed early; topline data are expected in the first half of 2027. A Phase III study for ocular myasthenia gravis is planned to start in H1 2027, and the Sjögren’s study is recruiting more strongly than expected. The company emphasizes the broad potential of the BAFF-/APRIL inhibitor, based on experience in China with more than 10,000 treated patients, and is now focusing on regulatory preparation, manufacturing and commercial readiness. » More on de.investing.com

Financials

In the last quarter, Vor Biopharma had revenue of €0 and net profit of -€76.57M
(EUR) September 2026
YoY
Revenue 0 -
Gross profit 0 -
Net profit -76.57M 88.94%
EBITDA -76.53M 88.95%

Fundamentals

Metric Value
Market capitalization
€957.3M
Number of shares
54.19M
52-week high/low
€23.65 - €5.91
Dividends No
Beta
1.83
P/E ratio
0.06
PEG ratio
0.00
P/B ratio
-8.45
P/S ratio
0.00

Company profile

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Name
Vor Biopharma
CEO
Jean-Paul Kress
Website
IPO
02/05/2021
Employees 76
🍪

Parqet  uses cookies. Learn more